Search all trials

Find therapies in clinical trials near you – page 122

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 982
countries: 28
conditions: 2 106

3 982 trials recruiting28 European countries2 106 conditions coveredUpdated today

Quick filters

Hormone-dependent prostate cancer+1

Not recruiting

A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy

Registered drug

A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Enzalutamide

Contact Research Centre

Type 2 diabetes mellitus

Not recruiting

A study testing ALN-4324 for safety and effectiveness in overweight to obese patients with type 2 diabetes

Investigational

A study testing ALN-4324 for safety and effectiveness in overweight to obese patients with type 2 diabetes

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:ALN-4324

Contact Research Centre

Dementia Alzheimer's type

Not recruiting

Study of Trontinemab Compared to Placebo for Patients with Early Symptomatic Alzheimer's Disease

Registered drug

Study of Trontinemab Compared to Placebo for Patients with Early Symptomatic Alzheimer's Disease

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Florbetaben (18F)

Contact Research Centre

Dementia Alzheimer's type

Not recruiting

A study testing trontinemab compared to placebo in patients with early Alzheimer's disease including mild cognitive impairment and mild dementia

Registered drug

A study testing trontinemab compared to placebo in patients with early Alzheimer's disease including mild cognitive impairment and mild dementia

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Florbetaben (18F)

Contact Research Centre

Multiple sclerosis

Not recruiting

A Study Comparing Two Forms of Ocrelizumab Given Under the Skin in Patients with Multiple Sclerosis

Registered drugNo placebo

A Study Comparing Two Forms of Ocrelizumab Given Under the Skin in Patients with Multiple Sclerosis

Registered drugNo placebo

Poland

Participants:18–64 years
Substances:Ocrelizumab

Contact Research Centre

Prostate cancer

Not recruiting

Study of xaluritamig compared to cabazitaxel or androgen receptor therapy for patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo

Study of xaluritamig compared to cabazitaxel or androgen receptor therapy for patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate

Contact Research Centre

Colorectal cancer metastatic

Not recruiting

A Study Comparing Telisotuzumab Adizutecan to Trifluridine, Tipiracil, and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer

Registered drugNo placebo

A Study Comparing Telisotuzumab Adizutecan to Trifluridine, Tipiracil, and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Bevacizumab

Contact Research Centre

Squamous cell carcinoma of head and neck

Not recruiting

A study comparing BNT113 combined with pembrolizumab versus pembrolizumab alone for patients with HPV16-positive head and neck cancer that cannot be removed by surgery

Registered drugNo placebo

A study comparing BNT113 combined with pembrolizumab versus pembrolizumab alone for patients with HPV16-positive head and neck cancer that cannot be removed by surgery

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Pembrolizumab

Contact Research Centre

Ovarian cancer

Not recruiting

Study of tuvusertib combined with niraparib or lartesertib for patients with ovarian cancer that worsened after previous PARP inhibitor treatment

Registered drugNo placebo

Study of tuvusertib combined with niraparib or lartesertib for patients with ovarian cancer that worsened after previous PARP inhibitor treatment

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Tuvusertib

Contact Research Centre

Obesity+1

Not recruiting

A study testing maridebart cafraglutide for weight loss in adults with overweight or obesity, with or without type 2 diabetes

Investigational

A study testing maridebart cafraglutide for weight loss in adults with overweight or obesity, with or without type 2 diabetes

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Maridebart Cafraglutide

Contact Research Centre

Type 2 diabetes mellitus

Not recruiting

Study comparing cagrilintide and semaglutide versus tirzepatide in people with type 2 diabetes taking metformin or SGLT2 inhibitor

Registered drugNo placebo

Study comparing cagrilintide and semaglutide versus tirzepatide in people with type 2 diabetes taking metformin or SGLT2 inhibitor

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Cagrilintide

Contact Research Centre

Alcoholic liver disease

Not recruiting

A study testing NNC0194-0499, cagrilintide, and semaglutide alone or combined to treat liver damage in people with alcohol-related liver disease

Investigational

A study testing NNC0194-0499, cagrilintide, and semaglutide alone or combined to treat liver damage in people with alcohol-related liver disease

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Cagrilintide

Contact Research Centre

Find therapies in clinical trials near you – page 122

2 729 trials match your criteria

Hormone-dependent prostate cancer+1

A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy

Type 2 diabetes mellitus

A study testing ALN-4324 for safety and effectiveness in overweight to obese patients with type 2 diabetes

Dementia Alzheimer's type

Study of Trontinemab Compared to Placebo for Patients with Early Symptomatic Alzheimer's Disease

Dementia Alzheimer's type

A study testing trontinemab compared to placebo in patients with early Alzheimer's disease including mild cognitive impairment and mild dementia

Multiple sclerosis

A Study Comparing Two Forms of Ocrelizumab Given Under the Skin in Patients with Multiple Sclerosis

Prostate cancer

Study of xaluritamig compared to cabazitaxel or androgen receptor therapy for patients with metastatic castration-resistant prostate cancer

Colorectal cancer metastatic

A Study Comparing Telisotuzumab Adizutecan to Trifluridine, Tipiracil, and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer

Squamous cell carcinoma of head and neck

A study comparing BNT113 combined with pembrolizumab versus pembrolizumab alone for patients with HPV16-positive head and neck cancer that cannot be removed by surgery

Ovarian cancer

Study of tuvusertib combined with niraparib or lartesertib for patients with ovarian cancer that worsened after previous PARP inhibitor treatment

Obesity+1

A study testing maridebart cafraglutide for weight loss in adults with overweight or obesity, with or without type 2 diabetes

Type 2 diabetes mellitus

Study comparing cagrilintide and semaglutide versus tirzepatide in people with type 2 diabetes taking metformin or SGLT2 inhibitor

Alcoholic liver disease

A study testing NNC0194-0499, cagrilintide, and semaglutide alone or combined to treat liver damage in people with alcohol-related liver disease

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.